Is MYOV or DIVO a better dividend investment in 2026?

MYOV currently yields 7.41% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: MYOV offers higher current income.

What is the dividend yield difference between MYOV and DIVO?

MYOV has a forward dividend yield of 7.41% ($2.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 0.92 percentage points.

Home › Compare › MYOV vs DIVO

MYOV vs DIVO: Dividend Comparison 2026

MYOV yields 7.41% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MYOV wins by $1.9K in total portfolio value

INVESTMENT

TIME HORIZON10 years

MYOV

● Live price

7.41%

Share price

$26.98

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$32.7K

Annual income

$1,186.18

Full MYOV calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — MYOV vs DIVO

📍 MYOV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MYOV	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MYOV + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MYOV pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYOV

Annual income on $10K today (after 15% tax)

$630.10/yr

After 10yr DRIP, annual income (after tax)

$1,008.25/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, MYOV beats the other by $173.83/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYOV + DIVO for your $10,000?

MYOV: 50%DIVO: 50%

100% DIVO50/50100% MYOV

Portfolio after 10yr

$31.7K

Annual income

$1,083.93/yr

Blended yield

3.42%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MYOV right now

MYOV

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-3.0

Piotroski

2/9

DIVO

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYOV buys

DIVO buys

No recent congressional trades found for MYOV or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMYOVDIVO

Forward yield	7.41% ✓	6.49%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$32.7K ✓	$30.7K
Annual income after 10y	$1,186.18 ✓	$981.68
Total dividends collected	$9.7K ✓	$8.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: MYOV vs DIVO ($10,000, DRIP)

Year	MYOV Portfolio	MYOV Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$11,441	$741.29	$11,349	$649.42	+$92.00 → MYOV
2	$13,035	$792.65	$12,833	$688.83	+$202.00 → MYOV
3	$14,791	$843.97	$14,459	$727.90	+$332.00 → MYOV
4	$16,722	$895.04	$16,238	$766.49	+$484.00 → MYOV
5	$18,838	$945.65	$18,179	$804.47	+$659.00 → MYOV
6	$21,152	$995.63	$20,293	$841.71	+$859.00 → MYOV
7	$23,678	$1,044.81	$22,591	$878.14	+$1.1K → MYOV
8	$26,428	$1,093.05	$25,087	$913.65	+$1.3K → MYOV
9	$29,418	$1,140.20	$27,791	$948.18	+$1.6K → MYOV
10	$32,664	$1,186.18	$30,718	$981.68	+$1.9K → MYOV

MYOV vs DIVO: Complete Analysis 2026

MYOV — Stock

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Full MYOV Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this MYOV vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYOV vs SCHD MYOV vs JEPI MYOV vs O MYOV vs KO MYOV vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.